Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,604.85INR
28 Apr 2017
Change (% chg)

Rs11.55 (+0.45%)
Prev Close
Rs2,593.30
Open
Rs2,612.00
Day's High
Rs2,612.00
Day's Low
Rs2,585.55
Volume
13,748
Avg. Vol
39,207
52-wk High
Rs3,689.00
52-wk Low
Rs2,560.00

REDY.BO

Chart for REDY.BO

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.15
Market Cap(Mil.): Rs432,694.09
Shares Outstanding(Mil.): 165.74
Dividend: 20.00
Yield (%): 0.77

Financials

  REDY.BO Industry Sector
P/E (TTM): -- 29.41 30.38
EPS (TTM): -- -- --
ROI: -- 13.85 13.36
ROE: -- 14.79 14.50

BRIEF-Dr. Reddy's Labs launches Ezetimibe and Simvastatin tablets in U.S. market

* Says launch of Ezetimibe and Simvastatin tablets in U.S. market Source text for Eikon: Further company coverage:

27 Apr 2017

BRIEF-Fresenius sees no change in relationship of Merck KGaA's unit with partner Dr Reddy's

* Fresenius ceo sturm says we've had a good q1 but will not provide details

25 Apr 2017

BRIEF-Dr.Reddy's Laboratories announces launch of progesterone capsules in the U.S.

* Dr.Reddy's Laboratories - announces the launch ofprogesterone capsules in the U.S. market". Source text: (http://bit.ly/2pLTt0P) Further company coverage:

21 Apr 2017

BRIEF-Dr. Reddy's Labs, Integra Lifesciences sign deal to market Duragen products in India

* Co, Integra Lifesciences enter agreement to market, distribute Duragen plus and suturable duragen dural regeneration in India

27 Mar 2017

BRIEF-Cytosorbents Corp enters into a partnership with Dr. Reddy's laboratories

* Have entered into a partnership with Dr. Reddy's laboratories ltd for South African market

16 Mar 2017

BRIEF-Dr.Reddy's Labs gets form 483 with 3 observations from USFDA for audit of Miryalaguda plant

* Says the audit of API manufacturing plant at Miryalaguda, by the US FDA, has been completed on February 21, 2017

21 Feb 2017

BRIEF-Dr.Reddy's Labs says no claims against co for monetary damages

* Clarifies on news item "Dr. Reddy's announces US district court's opinion relating to patent infringement"

17 Feb 2017

BUZZ-India's Dr. Reddy's Labs hits over 1-year low; firm's drug infringes U.S. patents

** Shares of Dr Reddy's Laboratories fall as much as 3.9 pct, their lowest since Jan 22, 2016

16 Feb 2017

BRIEF-Dr Reddy's says U.S. court finds co's product infringes some patents

* Says Dr. Reddy's Laboratories announces U.S. district court's opinion relating to patent infringement

16 Feb 2017

BRIEF-Dr.Reddy's Labs says co not served with legal papers in matter as in Mezzion's press release

* Dr.Reddy's Laboratories clarifies on news item "Korean biotech firm Mezzion Pharma files suit against Dr Reddy's laboratories."

27 Jan 2017

More From Around the Web

Earnings vs. Estimates